His main research concerns Osteoprotegerin, Internal medicine, Osteoclast, Endocrinology and Bone resorption. His work deals with themes such as Tumor necrosis factor alpha, Molecular biology and Arthritis, which intersect with Osteoprotegerin. Colin R. Dunstan studies Internal medicine, namely Bone cell.
His Osteoclast study integrates concerns from other disciplines, such as RANK Ligand, RANKL, Pathology, Cell biology and Bone disease. His work on Bone remodeling and Osteoporosis as part of his general Endocrinology study is frequently connected to Arterial calcification, thereby bridging the divide between different branches of science. As a part of the same scientific family, Colin R. Dunstan mostly works in the field of Bone resorption, focusing on Resorption and, on occasion, Cytoskeleton.
Colin R. Dunstan spends much of his time researching Internal medicine, Endocrinology, Osteoprotegerin, Bone resorption and Osteoclast. His Internal medicine study frequently involves adjacent topics like Genetically modified mouse. The study incorporates disciplines such as Receptor and Osteoblast in addition to Endocrinology.
Colin R. Dunstan is involved in the study of Osteoprotegerin that focuses on RANK Ligand in particular. Colin R. Dunstan has included themes like Bone remodeling and Resorption in his Bone resorption study. His Osteoclast research includes themes of Molecular biology and Pathology.
His primary areas of investigation include Biomedical engineering, Bone regeneration, Cancer research, Scaffold and Cancer cell. His study in Cancer research is interdisciplinary in nature, drawing from both Pathology, Signal transduction, Metastasis, Triple-negative breast cancer and Prostate cancer. His research in Signal transduction intersects with topics in Endocrinology, Gene knockdown, Calcitriol receptor, Internal medicine and Breast cancer.
He combines subjects such as Osteoclast and Multiple myeloma with his study of Endocrinology. His studies in Multiple myeloma integrate themes in fields like Osteoprotegerin and Bone disease. Bone resorption is closely connected to Bone remodeling in his research, which is encompassed under the umbrella topic of Osteoblast.
Colin R. Dunstan mainly focuses on Bone regeneration, Cancer research, Biomedical engineering, Osteoblast and Bone cell. His research on Cancer research also deals with topics like
The Osteoblast study combines topics in areas such as Noggin and Cell biology. His Bone cell course of study focuses on Bone remodeling and Osteoclast. His research in Osteoclast focuses on subjects like Mechanobiology, which are connected to Bone resorption.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
D.L Lacey;E Timms;H.-L Tan;M.J Kelley.
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
W.S Simonet;D.L Lacey;C.R Dunstan;M Kelley.
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Young-Yun Kong;Hiroki Yoshida;Ildiko Sarosi;Hong-Lin Tan.
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
N. Bucay;I. Sarosi;C. R. Dunstan;S. Morony.
Genes & Development (1998)
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
Hailing Hsu;David L. Lacey;Colin R. Dunstan;Irina Solovyev.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Increased bone formation in osteocalcin-deficient mice
Patricia Ducy;Christelle Desbois;Brendan Boyce;Gerald Pinero.
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
L C Hofbauer;S Khosla;C R Dunstan;D L Lacey.
Journal of Bone and Mineral Research (2000)
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Mark A. Lomaga;Wen Chen Yeh;Ildiko Sarosi;Gordon S. Duncan.
Genes & Development (1999)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
Ji Li;Ildiko Sarosi;Xiao-Qiang Yan;Sean Morony.
Proceedings of the National Academy of Sciences of the United States of America (2000)
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
Teresa L. Burgess;Yi-xin Qian;Stephen Kaufman;Brian D. Ring.
Journal of Cell Biology (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: